| Identification | More | [Name]
Nifekalant | [CAS]
130636-43-0 | [Synonyms]
1,3-dimethyl-6-[2-(n-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino]-2,4(1h,3h)-pyrimidinedione hydrochloride
6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethyl-pyrimidine-2,4-dione
6-((2-((2-hydroxyethyl)(3-(p-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-uracil
NIFEKALANT
NIFEKALANT HCL
NIFEKALANT HYDROCHLORIDE
NIFEKALANT [6-((2-((2-HYDROXYETHYL)(3-(P-NITROPHENYL)PROPYL)AMINO)ETHYL)AMINO)-1,3-DIMETHYL-URACIL] | [Molecular Formula]
C19H27N5O5 | [MDL Number]
MFCD00892243 | [Molecular Weight]
405.45 | [MOL File]
130636-43-0.mol |
| Hazard Information | Back Directory | [Uses]
Nifekalant (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC50 of 10 μM. Nifekalant can be used for refractory ventricular tachyarrhythmias research[1][2]. | [Definition]
ChEBI: Nifekalant is an amine. | [in vivo]
In rats (a species deficient in functional cardiac IK), before coronary ligation, 3 mg/kg and 10 mg/kg MS-551 decreased the heart rate by 6% and 12%, and increased mean arterial pressure (MAP) by 14% and 33%, respectively. MS-551 prolongs the QT interval and reduced the incidence of sustained ventricular fibrillation (VF) after reperfusion[3]. | [References]
[1] Lü-Pei Du, et al. The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4771-7. DOI:10.1016/j.bmcl.2004.06.070
[2] Ioannis N Pantazopoulos, et al. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011 Jun 26;3(6):169-76. DOI:10.4330/wjc.v3.i6.169
[3] J Chen, et al. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. DOI:10.1111/j.1476-5381.1996.tb15762.x |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|